阿托伐他汀与辛伐他汀治疗原发性高脂血症的疗效比较观察

目的观察比较阿托伐他汀和辛伐他汀治疗原发性高脂血症的临床疗效与安全性。方法将80例原发性高血脂患者随机分为阿托伐他汀组(10mg/次,每天1次)和辛伐他汀组(10mg/次,每天1次),每组40例。治疗结束后比较2组血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平变化。结果治疗12周后,阿托伐他汀组降低TC、TG、LDL-C的总有效率均高于辛伐他汀组,差异均有统计学意义(P<0.05或P<0.01)。治疗12周末,2组患者TC、TG、LDL-C水平均显著下降,HDL-C水平均显著上升,差异均有统计学意义(P<0.05或P<0.01)。2组治疗前后丙氨酸氨基转移酶(ALT)、肌酐(Cr)、尿素氮(BUN)、肌酸激酶(CK)水平比较差异无统计学意义(P>0.05)。结论相同剂量下阿托伐他汀和辛伐他汀治疗原发性高脂血症安全、有效,但阿托伐他汀降脂效果更为显著。     

辛伐他汀与氟伐他汀治疗高脂血症的疗效比较

目的比较观察辛伐他汀与氟伐他汀治疗高脂血症的疗效。方法80例高脂血症患者随机分为A、B两组,在常规低脂膳食基础上,A组服用辛伐他汀20mg,B组服用氟伐他汀20mg,均1次/d,疗程为12周,检测两组患者治疗前后血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平的变化。结果服药12周末与治疗前相比,两组的TC、TG、LDL-C均显著下降(P<0.01);HDL-C均明显上升(P<0.05),但A组更为显著。结论辛伐他汀与氟伐他汀均为高效、安全的降脂药物,但辛伐他汀的降脂效果更为显著。     

辛伐他汀与阿托伐他汀治疗老年原发性高脂血症临床效果及安全性比较

目的：比较阿托伐他汀和辛伐他汀在老年原发性高脂血症治疗中的临床效果。方法124例患者随机分为A、B组各62例,A组给予阿托伐他汀治疗,B组给予辛伐他汀治疗,比较2组治疗前、治疗后4周、8周TC、TG、LDL-C、HDL-C水平变化及不良反应发生情况。结果治疗4周后A组降脂作用（ TC、TG、LDL-C水平下降）较B组明显（P﹤0.05）,而治疗8周后降脂作用相当;HDL-C水平升高较慢,至治疗8周后才有明显升高。结论阿托伐他汀较辛伐他汀起效快,总体降脂作用相当,均较显著。     

匹伐他汀治疗原发性高胆固醇血症的疗效与安全性评价

目的 评价匹伐他汀治疗原发性高胆固醇血症的疗效和安全性.方法 随机、单盲(对研究者设盲)、阳性药物平行对照.46例原发性高胆固醇血症患者随机分为匹伐他汀(2和4 mg)组和阿托伐他汀(10 mg)组,研究为期8周,观察治疗前后患者血脂[总胆固醇(TC)、高密度脂蛋白-胆固醇(HDL-C)、低密度脂蛋白-胆固醇(LDL-C)、甘油三酯(TG)]、丙氨酸氨基转移酶/天冬氨酸氨基转移酶(ALT/AST)及磷酸肌酸激酶(CPK)水平的变化.结果 治疗4和8周各组TC、LDL-C水平均明显降低(P<0.01), 且4周与8周无显著差异;治疗8周各组LDL-C达标率分别为62.5%、66.7%和86.7%;但3组HDL-C和TG水平治疗前后无明显变化.匹伐他汀(2 mg)组1例出现CPK水平异常升高,停药2周后恢复正常.结论 匹伐他汀能有效降低原发性高胆固醇血症患者的TC和LDL-C水平,疗效与阿托伐他汀相似,且基本安全.     

普罗布考联合阿托伐他汀对急性冠脉综合征血脂蛋白相关磷脂酶A2的影响

目的:评价普罗布考和阿托伐他汀联合应用对急性冠脉综合征(ACS)患者血脂及脂蛋白相关磷脂酶A2(Lp-PLA2)的影响.方法:将94例经冠脉造影证实的ACS患者随机分为2组:单药组48例,予以阿托伐他汀(20 mg/d)治疗;联合组46例,予以阿托伐他汀(20 mg/d)和普罗布考(500 mg/d)联合治疗.分别于治疗前和治疗后6～8周检测血Lp-PLA2和血总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平并进行比较分析.结果:2组治疗前TC、TG、LDL-C、HDL-C、Lp-PLA2水平比较差异无统计学意义(P＞0.05);2组治疗后TC、TG、LDL-C、Lp-PLA2较治疗前均降低,单药组治疗后HDL-C升高,联合组治疗后HDL-C下降,差异均有统计学意义(P＜0.01);联合组较单独治疗组治疗后TC、LDL-C、Lp-PLA2降低,差异均有统计学意义(P＜0.05),但TG差异无统计学意义(P＞0.05).结论:对ACS患者单独应用阿托伐他汀及联合普罗布考均能够有效降低TC、LDL-C、Lp-PLA2,但联合治疗疗效更为显著,对稳定斑块、抗动脉粥样硬化有重要意义.     

阿托伐他汀对心肌梗死患者血脂水平的影响

目的 探讨阿托伐他汀对心肌梗死患者血脂水平的影响.方法 58例心肌梗死患者随机分为观察组(采用阿托伐他汀治疗,29例)及对照组(采用烟酸缓释片治疗,29例),比较分析两组患者血脂水平变化.结果 两组治疗前总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)及低密度脂蛋白胆固醇(LDL-C)水平差异均无统计学意义(均P＞0.05);治疗后,两组TC、TG、LDL-C水平均有显著降低(t=8.56、7.98、9.12、9.95、8.02、7.64,均P＜0.05),且观察组TC、LDL-C水平显著低于对照组(=7.78、9.15,均P＜0.05).结论 阿托伐他汀对心肌梗死患者降脂疗效显著,安全可靠.     

不同剂量阿托伐他汀治疗颈动脉粥样硬化对比分析

目的 观察不同剂量阿托伐他汀对颈动脉粥样硬化的临床疗效.方法 选择存在有不同程度的颈动脉粥样硬化并有斑块形成的患者118例,随机分为2组.治疗组56例,服用阿托伐他汀20mg,每晚1次;对照组62例,服用阿托伐他汀10mg,每晚1次,疗程4个月(16周).观察治疗前后颈动脉内膜-中层厚度(IMT)以及胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)的变化.结果 阿托伐他汀10mg、20mg均能明显减轻颈动脉粥样硬化,降低TC、TG、LDL-C水平,升高HDL-C水平.治疗组较对照组能更进一步降低降低IMT(P＜0.05)、TC、LDL-C(P＜0.05)和升高HDL-C水平(P＜0.05).结论 阿托伐他汀可以明显减轻颈动脉粥样硬化病变,有效降低血脂水平,可作为治疗颈动脉粥样硬化的常规用药.     

不同剂量阿托伐他汀对比辛伐他汀治疗老年冠心病合并高脂血症的临床观察

目的:观察不同剂量阿托伐他汀对比辛伐他汀治疗老年冠心病合并高脂血症的临床疗效和安全性。方法:将150例老年冠心病合并高脂血症患者按随机数字表法均分为3组。观察Ⅰ组患者服用阿托伐他汀10 mg/d,qd;观察Ⅱ组患者服用阿托伐他汀20 mg/d,qd;对照组患者服用辛伐他汀20 mg/d,qd。8周为1个疗程,根据患者情况选择性治疗1～3个疗程。观察比较各组治疗前及治疗4、8周后的血脂水平[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、治疗8周后的总有效率以及治疗过程中的不良反应发生率。结果:治疗4周后,3组患者TC、TG、LDL-C、HDL-C水平均较治疗前显著改善(P<0.05),但组间比较差异无统计学意义(P>0.05);治疗8周后,3组患者TC、TG、LDL-C、HDL-C水平均较治疗前显著改善(P<0.05),且观察Ⅱ组患者TC、TG、LDL-C水平均显著低于观察Ⅰ组及对照组患者(P<0.05),而观察Ⅰ组患者各血脂指标与对照组患者比较差异均无统计学意义(P>0.05)。治疗8周后,观察Ⅱ组患者总有效率显著高于观察Ⅰ组及对照组患者(P<0.05),而观察Ⅰ组患者总有效率与对照组患者比较差异无统计学意义(P>0.05)。3组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论:阿托伐他汀治疗老年冠心病合并高脂血症疗效较好,且对剂量有显著依赖性,适当增大剂量,治疗效果优于辛伐他汀,且不良反应发生率并不增加。     

阿托伐他汀强化降脂对高血压病患者颈动脉粥样硬化的影响

目的观察合并有颈动脉粥样硬化的高血压病患者阿托伐他汀强化降脂后颈动脉内膜中膜厚度（CIMT）的变化。方法选择伴有不同程度的颈动脉粥样硬化的高血压病患者126例,随机分为2组。A组（强化治疗组）65例,服用阿托伐他汀40mg,每晚1次;B组（常规治疗组）61例,服用阿托伐他汀10mg,每晚1次,疗程6个月。观察治疗前后CIMT以及总胆固醇（TC）、甘油三脂（TG）、低密度脂蛋白胆固醇（LDL-C）和高密度脂蛋白胆固醇（HDL-C）的变化。结果阿托伐他汀40mg、10mg（P〈0.05）、TC、LDL-C（P〈0.05）和升高HDL-C水平（P〈0.05）。结论阿托伐他汀强化降脂能更有效地降低CIMT,以及TC和LDL-C水平,并具有良好的安全性。     

不同剂量阿托伐他汀对2型糖尿病患者心血管并发症的影响

目的:观察不同剂量阿托伐他汀对2型糖尿病患者心血管并发症的影响.方法:将150例2型糖尿病患者随机分为3组,对照组50例、常规降脂组50例(阿托伐他汀20 mg/d)、强化降脂组50例(阿托伐他汀40 mg/d).各组常规治疗包括抗血小板治疗和降糖(药物和/或胰岛素)治疗.均随访3年,观察各治疗组心血管并发症的发生情况,评价治疗效果.结果:与对照组相比,常规降脂组和强化降脂治疗后组TC、低密度脂蛋白-胆固醇(LDL-C)显著下降(P＜0.01),高密度脂蛋白-胆固醇(HDL-C)显著升高(P＜0.01).常规降脂组与强化降脂组治疗后比较,TC、LDL-C下降程度和HDL-C升高程度比较差异有统计学意义(P＜0.01).3年内主要心血管并发症与对照组相比,强化降脂组与常规降脂组比例明显降低(P＜0.05),且强化降脂组较常规降脂组心血管并发症发生比例明显降低(P＜0.05).结论:阿托伐他汀能显著减少2型糖尿病患者心血管并发症的发生,且强化降脂治疗效果更佳,无明显不良反应.     

阿托伐他汀和辛伐他汀调脂疗效的成本-效果分析

目的 比较阿托伐他汀与辛伐他汀片治疗高脂血症的成本与效果.方法 将110例确诊为冠心病的患者,随机分成两组:A组57例口服阿托伐他汀片(商品名:立普妥);B组53例口服辛伐他汀片(商品名:舒降之),同治疗8周.利用药物经济学的原理,采用成本-效果分析方法对阿托伐他汀与辛伐他汀治疗冠心病高脂血症的临床疗效进行评价.结果 阿托伐他汀和辛伐他汀的成本分别为752.80元和733.35元,辛伐他汀组降低总胆固醇和低密度脂蛋白的效果优于阿托伐他汀组,治疗成本-效果比也低于阿托伐他汀组.结论 辛伐他汀治疗冠心病高脂血症的经济效率优于阿托伐他汀.     

阿托伐他汀与辛伐他汀治疗高脂血症的效果对比

目的 对比阿托伐他汀与辛伐他汀治疗高脂血症的效果.方法 96例高脂血症患者,随机分为观察组与对照组,每组48例.对照组使用辛伐他汀治疗,观察组使用阿托伐他汀治疗.比较两组患者的临床治疗效果,治疗前后的血脂指标[总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]水平,...     

辛伐他汀联合阿昔莫司治疗混合型高脂血症的疗效与安全性研究

目的:评价辛伐他汀联合阿昔莫司治疗混合型高脂血症的疗效及安全性。方法:入选63例冠心病合并混合型高脂血症的患者,随机分为2组:辛伐他汀 阿昔莫司组(32例)和辛伐他汀组(31例)。2组患者均接受正规的抗心肌缺血治疗,辛伐他汀 阿昔莫司组给予辛伐他汀20mg/d,阿昔莫司500mg/d;辛伐他汀组给予辛伐他汀20mg/d,均连续治疗3个月。比较2组治疗前后血脂各项指标变化,并记录药物不良反应。结果:2组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)均较治疗前下降,辛伐他汀 阿昔莫司组TC、LDL-C、TG下降更为显著,并伴高密度脂蛋白胆固醇(HDL-C)升高。辛伐他汀 阿昔莫司组除皮肤反应发生率较高外,其他不良反应发生率2组相近。结论:辛伐他汀联合阿昔莫司能降低LDL-C和TC,并能升高HDL-C,是治疗混合型高脂血症的安全有效的疗法。     

The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study

ABSTRACT

Objective: To assess the incremental low-density lipoprotein-cholesterol (LDL-C) lowering efficacy of doubling the statin dose or switching to the ezetimibe/simvastatin 10/20?mg combination tablet (EZE/SIMVA) in patients on simvastatin 20?mg or atorvastatin 10?mg not at LDL-C target < 2.5?mmol/L.

Study design and methods: Patients with documented coronary heart disease (CHD) and/or type 2 diabetes (DM2) with LDL-C ≥ 2.5 and < 5.0?mmol/L despite treatment with atorvastatin 10?mg or simvastatin 20?mg were randomized to (1) double statin dose or (2) switch to ezetimibe/simvastatin 10/20, according to a PROBE study design. LDL-C, lipoprotein subfractions and safety data were assessed during the study.

Results: 119 of 178 (67%) patients in the EZE/SIMVA group and 49 of 189 (26%) in the doubling statin group reached target LDL-C < 2.5?mmol/L. The odds ratio of success for EZE/SIMVA versus doubling statin treatment in reaching the LDL-C target of < 2.5?mmol/L was 5.7 (95% CI: 3.7–9.0, p < 0.0001). A reduction in total cholesterol (TC), total/high density lipoprotein (HDL) cholesterol ratio and apolipoprotein B was observed in both groups, but this reduction was significantly more pronounced in the EZE/SIMVA group as compared with the doubling statin dose group. Treatment was well tolerated and no difference was observed between the two groups with regard to adverse effects.

Conclusions: In CHD/DM2 patients treated with simvastatin or atorvastatin with LDL-C persistently ≥ 2.5?mmol/L, switching to the EZE/SIMVA was more effective in attaining the LDL-C target of < 2.5?mmol/L than doubling the statin dose.     

阿托伐他汀治疗冠心病并高脂血症临床研究

目的 评价阿托代他汀治疗冠心病并高脂血症的疗效。方法 阿托伐他汀组(10mg/d)和辛代他汀组(20mg/d)连续服药8周。结果 治疗8周后，治疗组(阿托伐他汀组)降低胆固醇、甘油三酯及升高HDL-C的总有效率分别为85％、58％、56％，对照组(辛代他汀组)分别为50％、15％、50％。治疗组冠心病心脏性事件比对照组下降。结论 阿托伐他汀有明显的降脂作用，预防心脏性事件。     

Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.

Male Hartley guinea pigs were fed a hypercholesterolemic diet rich in lauric and myristic acids with 0, 10, or 20 mg/kg of simvastatin or atorvastatin for 21 days. Atorvastatin and simvastatin resulted in a lowering of plasma low-density lipoprotein (LDL) cholesterol in a dose-dependent manner by an average of 48 and 61% with 10 and 20 mg/kg, respectively. Both statins were equally effective in lowering plasma LDL cholesterol and apolipoprotein B (apo-B) levels. Atorvastatin and simvastatin treatments yielded LDL particles that differed in composition from the control. Due to the relevance of LDL oxidation and cholesteryl ester transfer in plasma to the progression of atherosclerosis, these parameters were analyzed after statin treatment. Atorvastatin and simvastatin treatment decreased the susceptibility of LDL particles to oxidation by 95% as determined by the formation of thiobarbituric acid reactive substances. An 80% decrease in the transfer of cholesteryl ester between high-density lipoprotein (HDL) and the apo-B-containing lipoproteins was observed after simvastatin and atorvastatin treatment. In addition, statin effects on plasma LDL transport were studied. Simvastatin- and atorvastatin-treated guinea pigs exhibited 125 and 175% faster LDL fractional catabolic rates, respectively, compared with control animals. No change in LDL apo-B flux was induced by either treatment; however, LDL apo-B pool size was reduced after statin treatment. Hepatic microsomal free cholesterol was lower in the atorvastatin and simvastatin groups. However, only atorvastatin treatment resulted in an 80% decrease of acyl-CoA:cholesterol acyltransferase activity (P < 0.001). In summary, atorvastatin and simvastatin had similar LDL cholesterol lowering properties, but these drugs modified LDL transport and hepatic cholesterol metabolism differently.     

辛伐他汀和阿西莫司联合治疗混合型高脂血症病人的疗效和安全性

目的：观察辛伐他汀和阿西莫司联合治疗混合型高脂血症病人的疗效和安全性。方法：60例确诊为混合型高脂血症的门诊病人随机分成单药组（辛伐他汀20mg／d，po）和联合用药组（辛伐他汀20mg／d＋阿西莫司0．25g，bid，po），每组30例，进行随机、单盲、平行对照试验，疗程均为4周，观察两组病人降脂的疗效和不良反应发生情况。结果：经过4周治疗，两组病人血清总胆固醇（Tc）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）浓度，TC与高密度脂蛋白胆固醇（HDL-C）浓度的差值和HDL-C浓度的比值[（TC-HDL-C）／HDL-C]均显著降低，HDI，C浓度显著升高，但联合用药组TG浓度的降低和HDL-C浓度的升高明显优于单药组（P〈O．01），两组不良反应均较轻微和少见。结论：辛伐他汀和阿西莫司联合治疗混合型高脂血症病人的疗效明显，安全性好。     

阿托伐他汀治疗冠心病合并高脂血症的临床观察

目的:观察阿托伐他汀治疗冠心病合并高脂血症的临床疗效。方法:选取我院2008年6月-2010年9月213例确诊为冠心病合并高脂血症的患者为研究对象,随机分为治疗组(113例)和对照组(100例),2组均按冠心病伴高脂血症常规内科治疗,治疗组加用阿托伐他汀20mg,qd,口服。2组均8周为一疗程。治疗前后进行血、尿常规,血糖及肝、肾功能,心电图等指标检测,并对比其疗效。结果:治疗8周后,治疗组总胆固醇、甘油三酯、低密度脂蛋白、C反应蛋白、白细胞介素-6、肿瘤坏死因子-α、vonWill-ebrand因子、内皮素均较治疗前显著下降,高密度脂蛋白及一氧化氮均显著升高,治疗前后比较,差异有统计学意义(P<0.05),而对照组治疗前后上述指标比较无显著性差异(P>0.05);治疗组治疗后显效率及总有效率分别为77.0%和95.6%,与对照组(61.0%和76.0%)比较,差异有统计学意义(P<0.05)。结论:阿托伐他汀治疗冠心病合并高脂血症疗效确切,不良反应少。     

Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals

Purpose

There is significant inter-individual variability in the lipid-lowering effects of atorvastatin and simvastatin. Our goal was to investigate the impact of SLCO1B1 genetic polymorphism on the lipid-lowering effects of atorvastatin and simvastatin.

Methods

We recruited 363 unrelated hyperlipidemic patients with the CYP3A4*1/*1, CYP3A5*1/*1, and CYP3AP1*1/*1 genotypes: 189 of these were treated with atorvastatin and 174 were treated with simvastatin as a single-agent therapy (20 mg?day^?1 orally) for 4 weeks. The genotyping of SLCO1B1 c.521T?>?C (p.V174A, OATP-C*5) was performed with allele-specific polymerase chain reaction (AS-PCR), and PCR restriction fragment length polymorphism (RFLP) was performed to detect the carriers of SLCO1B1 c.388A?>?G (p.N130D, OATP-C*1b). Serum triglyceride (TGs), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels were determined before and after treatment.

Results

The frequencies of the SLCO1B1 521T?>?C and 388A?>?G variant alleles in Chinese hyperlipidemic patients were found to be 16.2% and 72.1% respectively. After treatment with 20 mg simvastatin or atorvastatin daily for 4 weeks, TC, TG, and LDL-C concentrations were lower than at baseline, on average, by 18.1?±?3.7%, 25.8?±?9.7%, 27.7?±?5.4% in the simvastatin-treated group, and 17.5?±?3.7%, 22.6?±?8.6%, 27.5?±?5.5% in the atorvastatin-treated group respectively, and the mean relative reduction in serum HDL cholesterol did not reach statistical significance (?1.0?±?10.9%, 0.5?±?9.3%). However, no significant differences were observed in the lipid-lowering effects of atorvastatin and simvastatin between subjects with different SLCO1B1 genotypes.

Conclusion

The SLCO1B1 521T?>?C and 388A?>?G variants were found to be relatively common in Chinese patients with essential hyperlipidemia. These frequencies were found to be similar to those observed in healthy Chinese and Japanese individuals, but significantly different from Caucasians and blacks. SLCO1B1 521T?>?C and 388A?>?G polymorphisms may not be associated with the lipid-lowering effects of atorvastatin and simvastatin.     

瑞舒伐他汀对急性冠状动脉综合征伴高脂血症患者血脂及炎性因子的影响

目的 观察瑞舒伐他汀治疗急性冠状动脉综合征(ACS)伴高脂血症的I临床疗效及安全性.方法 2010年9月至2011年1月就诊于北京安贞医院心内科的ACS伴高脂血症患者90例,完全随机分为辛伐他汀组(药物使用量:10 mg/d,n=42)和瑞舒伐他汀组(药物使用量:10 mg/d,n=48),疗程均为1周,观察治疗前后各项主要血脂指标变化率、达标率及血清肿瘤坏死因子仪(TNF-a)及C反应蛋白(CRP)变化.结果 在降低TC、LDL-C、脂蛋白(Lp)(a)及升高HDL-C方面,瑞舒伐他汀组优于辛伐他汀组[TC:瑞舒伐他汀组治疗后(4.80±0.36)mmol/L、治疗前(6.80±0.27)mmol/L、变化率-29%,辛伐他汀组分别为(5.50±0.19)mmoL/L、(6.90±0.21)mmol/L、-21%;LDL-C:瑞舒伐他汀组治疗后(2.00±0.26)mmol/L、治疗前(4.50±0.10)mmol/L、变化率-56%,辛伐他汀组(3.30±0.27)mmol/L、(4.00±0.21)mmol/L、-18%;Lp(a):瑞舒伐他汀组治疗后(72±15)mmol/L、治疗前(115±21)mmol/L、变化率一37%,辛伐他汀组(101±24)mmol/L、(108±21)mmoL/L、-6%;HDL-C:瑞舒伐他汀组治疗后(0.98±0.05)mmol/L、治疗前(0.72±0.04)mmol/L、变化率+36%,辛伐他汀组(0.90±0.02)mmol/L、(0.80±0.05)mmoL/L、+13%].2组对肝、肾功能的影响差异无统计学意义.舒伐他汀治疗组降低炎症标志物TNF-a和CRP水平强于辛伐他汀组[TNF-a:瑞舒伐他汀组治疗后(62+20)U/ml、治疗前(90±10)U/ml、变化率-31%,辛伐他汀组分别为(71±15)U/ml、(86±13)U/ml、-17%;CRP:瑞舒伐他汀组治疗后(2.7+1.6)mg/L、治疗前(4.8±1.8)mg/L、变化率-44%,辛伐他汀组(4.0±1.3)ms/L、(5.2±1.5)ms/L、-23%].2组患者治疗期间未出现明显的、难以耐受的不良反应.结论 瑞舒伐他汀(10 mg/d)可以更全面地调理ACS伴混合性高脂血症患者的血脂异常,尤其是在升高HDL-C、降低LDL-C方面,并具有良好的安全性.瑞舒伐他汀具有较强抗炎作用.

Abstract：

Objective To investigate the effects and the safety of rosuvastiatin in actute coronary syndrome (ACS)complicated with hyperlipidemia.Methods Ninety patients with hyperlipidernia were randomly assigned into simvastatin group (n=42) and rosuvastatin group(n=48).They were treated with simvasmtin and rosuvastatin respeetively 10 mg/d and 10 mg/d for 1 week.Lipid profile and physical laboratory investigations for adverse effects were also assessed.Serum levels of total cholesterol (TC),triglyceride (TG),low density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol(HDL-C)and Lp(a)were measured at the end of 1 weeks of the trial period. Results Rosuvastatin treatment was more effective than simvastatin in reducing serunl levels of TC,LDL-C and Lp(a)and in raising HDL-C.The difference of liver and kidney function of 2 groups was not statistically significant.The abilities of atorvastatin treatment group in decreasing inflammatory markers in TNF-a and CRP levels were stronger than those in the simvastatin group.Conclusion Rosuvastatin has full-scale lipid-regulating effects,especially in reducing serum levels of TC,LDL-C and Lp(a) and in raising HDL-C.